Gilteritinib for the Treatment of ALK NSCLC

Status Recruiting

Clinical Trial Summary

This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilteritinib against these resistant cells. Therefore, in this clinical trial, the investigators plan to study the effect of giltertinib in patients with ALK NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06225427
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Recruiting
Phase	Phase 1
Start date	May 2024
Completion date	March 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04267913` - Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)	Phase 2
Recruiting	`NCT04151940` - PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer	N/A
Terminated	`NCT03707925` - Bronchoscopic Laser Ablation of Peripheral Lung Tumors	N/A
Active, not recruiting	`NCT04081688` - Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC	Phase 1
Recruiting	`NCT04929041` - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Phase 2/Phase 3
Active, not recruiting	`NCT04250545` - Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer	Phase 1
Terminated	`NCT04396535` - Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04514497` - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	Phase 1
Withdrawn	`NCT05161533` - Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Phase 2
Recruiting	`NCT04919369` - All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	Phase 1
Terminated	`NCT03662074` - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04073745` - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer	Phase 1
Withdrawn	`NCT04186988` - [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy	Early Phase 1
Active, not recruiting	`NCT03600701` - Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT03637816` - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT04514484` - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Phase 1
Recruiting	`NCT05234307` - PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT06122064` - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer	N/A
Active, not recruiting	`NCT04533451` - Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT03776253` - Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer	N/A